QV Investors Inc. Has $15.95 Million Stock Position in Solventum Co. (NYSE:SOLV)

QV Investors Inc. lifted its holdings in shares of Solventum Co. (NYSE:SOLV - Free Report) by 15.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 209,792 shares of the company's stock after purchasing an additional 27,480 shares during the quarter. Solventum accounts for about 1.6% of QV Investors Inc.'s portfolio, making the stock its 19th biggest position. QV Investors Inc. owned about 0.12% of Solventum worth $15,953,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Czech National Bank raised its holdings in shares of Solventum by 5.9% during the first quarter. Czech National Bank now owns 31,743 shares of the company's stock worth $2,414,000 after acquiring an additional 1,777 shares during the period. Rhumbline Advisers increased its holdings in Solventum by 9.2% during the 1st quarter. Rhumbline Advisers now owns 300,263 shares of the company's stock worth $22,832,000 after purchasing an additional 25,339 shares in the last quarter. Parallel Advisors LLC raised its stake in shares of Solventum by 16.9% in the 1st quarter. Parallel Advisors LLC now owns 3,341 shares of the company's stock valued at $254,000 after purchasing an additional 483 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Solventum by 10,315.8% in the first quarter. GAMMA Investing LLC now owns 346,742 shares of the company's stock valued at $26,366,000 after purchasing an additional 343,413 shares in the last quarter. Finally, AdvisorNet Financial Inc boosted its position in shares of Solventum by 34.6% during the first quarter. AdvisorNet Financial Inc now owns 4,209 shares of the company's stock worth $320,000 after buying an additional 1,082 shares during the period.

Solventum Stock Performance

SOLV stock traded up $1.11 during trading hours on Tuesday, reaching $74.23. The stock had a trading volume of 1,135,793 shares, compared to its average volume of 1,225,359. The stock has a 50-day simple moving average of $69.42 and a 200 day simple moving average of $71.36. Solventum Co. has a fifty-two week low of $47.16 and a fifty-two week high of $85.92. The stock has a market capitalization of $12.84 billion and a PE ratio of 34.37. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83.

Solventum (NYSE:SOLV - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.19 by $0.15. The firm had revenue of $2.07 billion during the quarter, compared to analyst estimates of $2.02 billion. Solventum's revenue for the quarter was up 2.7% compared to the same quarter last year. During the same period in the previous year, the company posted $2.08 EPS. Analysts predict that Solventum Co. will post 6.58 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on SOLV. Piper Sandler raised Solventum from a "neutral" rating to an "overweight" rating and lifted their target price for the company from $78.00 to $87.00 in a research report on Monday, May 19th. Wells Fargo & Company lifted their price objective on shares of Solventum from $73.00 to $75.00 and gave the company an "equal weight" rating in a report on Friday, February 28th. Mizuho increased their target price on shares of Solventum from $70.00 to $82.00 and gave the stock a "neutral" rating in a report on Monday, March 3rd. The Goldman Sachs Group raised their target price on shares of Solventum from $63.00 to $71.00 and gave the company a "sell" rating in a research report on Monday, March 3rd. Finally, Morgan Stanley boosted their price target on shares of Solventum from $73.00 to $80.00 and gave the stock an "equal weight" rating in a research report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $80.29.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.